You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》匯豐研究下調信達生物(01801.HK)目標價至55元 評級「買入」
阿思達克 04-11 10:07
匯豐發表評級報告指,受到強勁生物仿製藥的銷售,信達生物(01801.HK)去年產品銷售收入為40億元人民幣,略超出該行預期。 該行將公司在2022年及2023年產品銷售分別上調4%至59億元人民幣,和6%至83億元人民幣,以反映禮來兩項新的認可資產銷售。在盈利方面,該行提高公司在2022年和2023年淨虧損預測至分別31億元人民幣及25億元人民幣(早前淨虧損預測為20億元人民幣及17億元人民幣)。 該行指,禮來於今年推出兩種BD藥物,料會帶動公司銷售額,故將公司在2022年至23年收入預測上調5%至8%,將其目標價由60元下調至55元,意味其股價有86%上行空間,維持其評級為「買入」。(ca/u) ~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account